Mode
Text Size
Log in / Sign up
Phase 2 Completed N=484 Prevention

Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

Source: ClinicalTrials.gov NCT00584844 ↗
Enrolled (actual)
484
Serious AEs
1.5%
Results posted
Jul 2017
Primary outcomePrimary: Safety: Adverse Event Category Rates for All Vaccinations — 264; 162; 53; 48 Adverse events

Summary

This study is designed to determine the safety and immunogenicity of a Live Francisella tularensis Vaccine

Outcome Measures

OutcomeResultp-value
PRIMARY
Safety: Adverse Event Category Rates for All Vaccinations
264; 162; 53; 48; 11; 10
SECONDARY
Immunogenicity: Protocol Compliant Post-primary Titer Rates
4.1; 95.9; 73.3; 26.7; 3.6; 96.4
SECONDARY
Immunogenicity: Protocol-compliant Post-boost 1 Titer Rates
22.2; 77.8; 100.0; 0; 43.8; 56.3
SECONDARY
Immunogenicity: Protocol-compliant Post-boost 2 Titer
5.6; 94.4; 25.0; 75.0; 6.3; 93.8

Eligibility Criteria

Inclusion Criteria:>

  • At least 18 years old, or if on active military duty, 17 years old >
  • Females of childbearing potential must agree to have a urine pregnancy test immediately before vaccination (Exception: documented hysterectomy or > 3 years of menopause). The results must be negative. Volunteers must agree not to become pregnant for 3 months after receipt of the vaccine.>
  • Subject must be actively enrolled in the SIP >
  • Subjects must be considered at risk for exposure to F. tularensis.>
  • Subjects must have an up-to-date (within 1 year) medical history, physical examination, and laboratory tests on their charts and be medically cleared for participation by an investigator. Examinations or tests may be repeated within 1 year at the discretion of the enrolling physician.>
  • Volunteer must be willing to return for all follow-up visits on days 1, 2, 7, once between days 12-16, and once between days 28-35, days 56-84 (if needed), all visits for serology, as well as an annual visit while enrolled in protocol.>
  • Volunteer must agree to report any Adverse Event which may or may not be associated with administration of the test article for at least 28 days after vaccination. All Serious and Unexpected Adverse Events will be reported for the duration of the volunteer's participation in the study. >

Exclusion Criteria:>

  • Clinically significant abnormal lab results including evidence of Hepatitis C*, Hepatitis B* carrier state, or elevated liver function tests (2X normal values or at discretion of PI).>
  • Personal history of an immunodeficiency or current treatment with an oral or intravenous immunosuppressive medication.>
  • Confirmed HIV* infection.>
  • Any other medical condition at the discretion of the PI.>
  • Antibiotic therapy for 7 days before vaccination.>
  • Females must not be pregnant or lactating (females must agree to not become pregnant for 3 months after vaccination).>
  • Any known allergies to excipients of the vaccine>
  • Administration of another live vaccine within 4 weeks or an inactivated vaccine (generally) within 7 days of tularemia vaccination.>
  • Any unresolved adverse event resulting from a previous immunization. >
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00584844). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search